{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T04:46:32Z","timestamp":1785732392509,"version":"3.56.0"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background and aims<\/jats:title>\n                    <jats:p>\n                      Few studies have evaluated the efficacy and safety of vonoprazan, cefuroxime, minocycline, and bismuth (VCMB) quadruple therapy (with vonoprazan 20 mg once daily and cefuroxime 250 mg twice daily) for\n                      <jats:italic>Helicobacter pylori<\/jats:italic>\n                      (\n                      <jats:italic>H. pylori<\/jats:italic>\n                      ) eradication. This retrospective pilot study aimed to assess the efficacy and safety of a 14-day VCMB regimen for\n                      <jats:italic>H. pylori<\/jats:italic>\n                      infection.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This retrospective analysis enrolled patients treated with a 14-day VCMB quadruple therapy. The included patients were 18\u201380 years old and positive for\n                      <jats:sup>1<\/jats:sup>\n                      <jats:sup>3<\/jats:sup>\n                      C urea breath test (\n                      <jats:sup>1<\/jats:sup>\n                      <jats:sup>3<\/jats:sup>\n                      C-UBT). VCMB quadruple therapy consists of vonoprazan 20 mg once daily, cefuroxime 250 mg twice daily, minocycline 100 mg twice daily and bismuth potassium citrate 220 mg twice daily.\n                      <jats:sup>1<\/jats:sup>\n                      <jats:sup>3<\/jats:sup>\n                      C-UBT was repeated 4\u20136 weeks after treatment to evaluate the\n                      <jats:italic>H. pylori<\/jats:italic>\n                      eradication efficacy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 106 patients were enrolled. The intention to treat (ITT) and per-protocol (PP) eradication rates were 90.6% (95% CI: 82.9\u201395.1) and 96.0% (95% CI: 89.5\u201398.7). The overall incidence of adverse events was 21.9%. Mild dizziness and nausea were the most common adverse events, and these symptoms resolved spontaneously without additional treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      The 14-day VCMB quadruple therapy, in which both vonoprazan and cefuroxime were administered at half their usual total daily doses, achieved a favorable\n                      <jats:italic>H. pylori<\/jats:italic>\n                      eradication rate, a low incidence of adverse events and good patient adherence. It is a potential new regimen for\n                      <jats:italic>H. pylori<\/jats:italic>\n                      eradication, further prospective multicenter studies are warranted to validate its efficacy and safety.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1897293","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T04:26:33Z","timestamp":1785731193000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of a reduced-drug burden quadruple therapy with vonoprazan, cefuroxime, minocycline, and bismuth for Helicobacter pylori eradication: a retrospective study"],"prefix":"10.3389","volume":"13","author":[{"given":"Xuefeng","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, The Shengli Clinical Medical College, Fujian Medical University","place":["Fuzhou, China"]},{"name":"Department of Gastroenterology, Fujian Provincial Hospital","place":["Fuzhou, China"]},{"name":"Department of Gastroenterology, Fuzhou University Affiliated Provincial Hospital","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghong","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The Shengli Clinical Medical College, Fujian Medical University","place":["Fuzhou, China"]},{"name":"Department of Gastroenterology, Fujian Provincial Hospital","place":["Fuzhou, China"]},{"name":"Department of Gastroenterology, Fuzhou University Affiliated Provincial Hospital","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simin","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Orthodontics, Affiliated Stomatological Hospital of Nanchang University","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1053\/j.gastro.2023.12.022","article-title":"Global prevalence of helicobacter pylori infection and incidence of gastric cancer between 1980 and 2022","volume":"166","author":"Chen","year":"2024","journal-title":"Gastroenterology."},{"key":"B2","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s10120-018-0876-0","article-title":"Effect of Helicobacter pylori eradication on the incidence of gastric cancer: a systematic review and meta-analysis","volume":"22","author":"Sugano","year":"2019","journal-title":"Gastric Cancer."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1053\/j.gastro.2016.01.028","article-title":"Association between helicobacter pylori eradication and gastric cancer incidence: a systematic review and meta-analysis","volume":"150","author":"Lee","year":"2016","journal-title":"Gastroenterology."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1097\/CM9.0000000000002546","article-title":"2022 Chinese national clinical practice guideline on Helicobacter pylori eradication treatment","volume":"135","author":"Zhou","year":"2022","journal-title":"Chin Med J."},{"key":"B5","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S0140-6736(18)32218-9","article-title":"Antibiotic allergy","volume":"393","author":"Blumenthal","year":"2019","journal-title":"Lancet."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e12804","DOI":"10.1111\/hel.12804","article-title":"The effect of previous eradication failure on antibiotic resistance of Helicobacter pylori: a retrospective study over 8 years in Beijing","volume":"26","author":"Li","year":"2021","journal-title":"Helicobacter."},{"key":"B7","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1007\/s11882-014-0476-y","article-title":"Penicillin and beta-lactam allergy: epidemiology and diagnosis","volume":"14","author":"Macy","year":"2014","journal-title":"Curr Allergy Asthma Rep."},{"key":"B8","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S0091-6749(96)70101-X","article-title":"Cross-reactivity between a penicillin and a cephalosporin with the same side chain","volume":"98","author":"Miranda","year":"1996","journal-title":"J Allergy Clin Immunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1007\/s10620-017-4564-4","article-title":"Randomized clinical trial: esomeprazole, bismuth, levofloxacin, and amoxicillin or cefuroxime as first-line eradication regimens for helicobacter pylori infection","volume":"62","author":"Fu","year":"2017","journal-title":"Dig Dis Sci."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e12956","DOI":"10.1111\/hel.12956","article-title":"New regimens as first-line eradication therapy for Helicobacter pylori infection in patients allergic to penicillin: a randomized controlled trial","volume":"28","author":"Zhang","year":"2023","journal-title":"Helicobacter."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1136\/gutjnl-2022-327745","article-title":"Management of helicobacter pylori infection: the Maastricht VI\/Florence consensus report","volume":"71","author":"Malfertheiner","year":"2022","journal-title":"Gut."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e13073","DOI":"10.1111\/hel.13073","article-title":"Application of cefuroxime in the eradication therapy of Helicobacter pylori infection: a review article","volume":"29","author":"Mi","year":"2024","journal-title":"Helicobacter."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/j.clinthera.2005.09.005","article-title":"Safety of doxycycline and minocycline: a systematic review","volume":"27","author":"Smith","year":"2005","journal-title":"Clin Ther."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1001\/archderm.1997.03890460044005","article-title":"Comparative safety of tetracycline, minocycline, and doxycycline","volume":"133","author":"Shapiro","year":"1997","journal-title":"Arch Dermatol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e12768","DOI":"10.1111\/hel.12768","article-title":"The appropriate cutoff gastric pH value for Helicobacter pylori eradication with bismuth-based quadruple therapy","volume":"26","author":"Ke","year":"2021","journal-title":"Helicobacter."},{"key":"B16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3390\/ph17060698","article-title":"Comparative efficacy and safety of potassium-competitive acid blockers vs","author":"Ouyang","year":"2024"},{"key":"B17","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/1751-2980.12334","article-title":"Esomeprazole, minocycline, metronidazole and bismuth as first-line and second-line regimens for Helicobacter pylori eradication","volume":"17","author":"Song","year":"2016","journal-title":"J Dig Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e13151","DOI":"10.1111\/hel.13151","article-title":"Tegoprazan-amoxicillin dual therapy for helicobacter pylori eradication: a prospective, randomized, multicenter study in Fujian, China","volume":"29","author":"Lin","year":"2024","journal-title":"Helicobacter."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1016\/j.cgh.2022.07.019","article-title":"Empirical second-line therapy in 5000 patients of the european registry on helicobacter pylori management (Hp-EuReg)","volume":"20","author":"Nyssen","year":"2022","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1007\/s10620-024-08460-3","article-title":"Bismuth-containing quadruple therapy for helicobacter pylori eradication: a randomized clinical trial of 10 and 14 days","volume":"69","author":"Ding","year":"2024","journal-title":"Dig Dis Sci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"970","DOI":"10.5009\/gnl230453","article-title":"Bismuth-based quadruple therapy as first-line treatment for clarithromycin-resistant helicobacter pylori infection: a prospective randomized comparison of 7- and 14-day treatment regimens","volume":"18","author":"Lim","year":"2024","journal-title":"Gut Liver."},{"key":"B22","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1097\/MCG.0000000000002001","article-title":"Vonoprazan is not inferior to proton pump inhibitors in bismuth-containing quadruple therapy for helicobacter pylori eradication: a meta-analysis of 10 studies from East Asia","volume":"58","author":"Cheng","year":"2024","journal-title":"J Clin Gastroenterol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"4279","DOI":"10.2147\/IJGM.S427450","article-title":"14-Day Vonoprazan-based bismuth quadruple therapy for treatment-na\u00efve patients with helicobacter pylori infection: a retrospective comparative study","volume":"16","author":"Lu","year":"2023","journal-title":"Int J Gen Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13099-022-00502-3","article-title":"Levofloxacin versus clarithromycin for Helicobacter pylori eradication: are 14 day regimens better than 10 day regimens?","volume":"14","author":"Azab","year":"2022","journal-title":"Gut Pathog."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e13148","DOI":"10.1111\/hel.13148","article-title":"Efficacy and safety of vonoprazan in dual\/triple\/quadruple regimens both in first-line and rescue therapy for helicobacter pylori eradication: a systematic review with meta-analysis","volume":"29","author":"Benito","year":"2024","journal-title":"Helicobacter."},{"key":"B26","doi-asserted-by":"publisher","first-page":"965","DOI":"10.3390\/antibiotics13100965","article-title":"Newer therapies for refractory helicobacter pylori infection in adults: a systematic review","volume":"13","author":"Liu","year":"2024","journal-title":"Antibiotics."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1111\/apt.13414","article-title":"The binding selectivity of vonoprazan (TAK-438) to the gastric H+, K+ -ATPase","volume":"42","author":"Scott","year":"2015","journal-title":"Aliment Pharmacol Ther."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1111\/apt.13588","article-title":"Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype","volume":"43","author":"Kagami","year":"2016","journal-title":"Aliment Pharmacol Ther."},{"key":"B29","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1159\/000504939","article-title":"Effectiveness and safety of vonoprazan versus proton pump inhibitors for second-line helicobacter pylori eradication therapy: systematic review and meta-analysis","volume":"102","author":"Shinozaki","year":"2021","journal-title":"Digestion."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.5152\/tjg.2026.25645","article-title":"Comparative effectiveness of vonoprazan dosing strategies in bismuth-based quadruple therapy for helicobacter pylori eradication: a prospective non-inferiority cohort study","author":"Yan","year":"2026","journal-title":"Turk J Gastroenterol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12876-019-1056-3","article-title":"Cefuroxime, levofloxacin, esomeprazole, and bismuth as first-line therapy for eradicating Helicobacter pylori in patients allergic to penicillin","volume":"19","author":"Song","year":"2019","journal-title":"BMC Gastroenterol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"e70033","DOI":"10.1111\/hel.70033","article-title":"Efficacy and safety of cefuroxime-tetracycline-containing bismuth quadruple therapy for helicobacter pylori eradication in penicillin-allergic patients: a multicenter randomized controlled trial","volume":"30","author":"Wang","year":"2025","journal-title":"Helicobacter."},{"key":"B33","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1086\/514622","article-title":"The pharmacodynamics of beta-lactams","volume":"27","author":"Turnidge","year":"1998","journal-title":"Clin Infect Dis."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e0060924","DOI":"10.1128\/mbio.00609-24","article-title":"Synergistic effects of sulopenem in combination with cefuroxime or durlobactam against Mycobacterium abscessus","volume":"15","author":"Dousa","year":"2024","journal-title":"MBio."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e70133","DOI":"10.1111\/hel.70133","article-title":"High-dose dual therapy versus bismuth-containing quadruple therapy as rescue treatment for helicobacter pylori infection: systematic review and meta-analysis","volume":"31","author":"Zhang","year":"2026","journal-title":"Helicobacter."},{"key":"B36","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1080\/00365521.2022.2119097","article-title":"Single-capsule bismuth-based quadruple therapy as a rescue therapy for Helicobacter pylori eradication","volume":"58","author":"Correia","year":"2023","journal-title":"Scand J Gastroenterol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1897293\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T04:26:34Z","timestamp":1785731194000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1897293\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":36,"alternative-id":["10.3389\/fmed.2026.1897293"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1897293","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]},"article-number":"1897293"}}